Drug-induced hepatotoxicity in cancer patients - implication for treatment

Vincenzi, Bruno; Armento, Grazia; Ceruso, Mariella Spalato; Catania, Giovanna; Leakos, Mark; Santini, Daniele; Minotti, Giorgio; Tonini, Giuseppe

doi:10.1080/14740338.2016.1194824

Cited by 69 publications

(45 citation statements)

References 175 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Selective therapeutic targeting remains a critical concern considering the minimal number of drug approvals by FDA, mostly due to non-specific accumulation and toxicity in clinical trials (Printz, 2011; Vincenzi et al, 2016). Therefore, we next compared the selective BaCa gain of function with anti-Fc crosslinking, a nonspecific way to induce DR5 receptor clustering (Wilson et al, 2011).…”

Section: Resultsmentioning

confidence: 99%

A Single-Agent Dual-Specificity Targeting of FOLR1 and DR5 as an Effective Strategy for Ovarian Cancer

et al. 2018

View full text Add to dashboard Cite

Therapeutic antibodies targeting ovarian cancer (OvCa)-enriched receptors have largely been disappointing due to limited tumor-specific antibody-dependent cellular cytotoxicity. Here we report a symbiotic approach that is highly selective and superior compared with investigational clinical antibodies. This bispecific-anchored cytotoxicity activator antibody is rationally designed to instigate "cis" and "trans" cytotoxicity by combining specificities against folate receptor alpha-1 (FOLR1) and death receptor 5 (DR5). Whereas the in vivo agonist DR5 signaling requires FcγRIIB interaction, the FOLR1 anchor functions as a primary clustering point to retain and maintain a high level of tumor-specific apoptosis. The presented proof of concept study strategically makes use of a tumor cell-enriched anchor receptor for agonist death receptor targeting to potentially generate a clinically viable strategy for OvCa.

show abstract

Section: Resultsmentioning

confidence: 99%

A Single-Agent Dual-Specificity Targeting of FOLR1 and DR5 as an Effective Strategy for Ovarian Cancer

et al. 2018

View full text Add to dashboard Cite

show abstract

“…For instance, kava is a traditional herbal remedy with proven anxiolytic and antidepressant properties but has been associated with hepatotoxicity (Teschke, ). This can be detrimental for cancer patients who often have compromised liver function as a side effect from chemotherapy (Vincenzi et al, ). However, aqueous extracts were reported to be safe in preclinical testing (Sarris et al, ; Sarris, Stough, Bousman, et al, ).…”

Section: Discussionmentioning

confidence: 99%

Herbal medicine for depression and anxiety:Asystematic review with assessment of potential psycho‐oncologic relevance

Yeung

Hernandez

Mao

et al. 2018

Phytotherapy Research

176

100

View full text Add to dashboard Cite

Anxiety and depression are prevalent among cancer patients, with significant negative impact. Many patients prefer herbs for symptom relief to conventional medications which have limited efficacy/side effects. We identified single-herb medicines that may warrant further study in cancer patients. Our search included PubMed, Allied and Complementary Medicine, Embase, and Cochrane databases, selecting only single-herb randomized controlled trials between 1996 and 2016 in any population for data extraction, excluding herbs with known potential for interactions with cancer treatments. One hundred articles involving 38 botanicals met our criteria. Among herbs most studied (≥6 randomized controlled trials each), lavender, passionflower, and saffron produced benefits comparable to standard anxiolytics and antidepressants. Black cohosh, chamomile, and chasteberry are also promising. Anxiety or depressive symptoms were measured in all studies, but not always as primary endpoints. Overall, 45% of studies reported positive findings with fewer adverse effects compared with conventional medications. Based on available data, black cohosh, chamomile, chasteberry, lavender, passionflower, and saffron appear useful in mitigating anxiety or depression with favorable risk-benefit profiles compared to standard treatments. These may benefit cancer patients by minimizing medication load and accompanying side effects. However, well-designed larger clinical trials are needed before these herbs can be recommended and to further assess their psycho-oncologic relevance.

show abstract

“…As an important stereoisomer of glycyrrhizic acid, MgIG is commonly used as a hepatoprotective medicine, which induces fewer side-effects than other similar treatments (25). Furthermore, it has been demonstrated that MgIG exhibits hepatoprotective activity against the hepatotoxicity induced by anticancer drugs (10), in a liver injury model induced by hepatectomy (6) and in a hypoxia/reoxygenation injury (ischemia/reperfusion) model in liver cells (8). The results of the present indicated that MgIG exhibits hepato-and cardioprotective effects.…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, MgIG protects liver cells from hypoxia-reoxygenation, ischemia/reperfusion and free fatty acid-induced injury (7)(8)(9). It has been suggested that MgIG exhibits potential hepatoprotective activity against hepatotoxicity induced by anticancer drugs (10). However, the effects and potential mechanisms of action of MgIG on the liver and heart remain unknown.…”

Section: Introductionmentioning

confidence: 99%

Magnesium isoglycyrrhizinate ameliorates doxorubicin‑induced acute cardiac and hepatic toxicity via anti‑oxidant and anti‑apoptotic mechanisms in mice

Zhang

Song

et al. 2017

Exp Ther Med

View full text Add to dashboard Cite

Abstract. The present study investigated the effects and potential mechanisms of action of magnesium isoglycyrrhizinate (MgIG) in doxorubicin (DOX)-treated mice. Histopathological analysis and western blot analysis were conducted in the liver and heart tissues and biochemical analysis of the serum was performed. The results revealed that MgIG (10, 20 and 40 mg/kg/day) could protect the structure and functions of the liver and heart by inhibiting the activities of the myocardial enzymes creatine kinase (CK), CK-MB and lactate dehydrogenase and the hepatic-specific enzymes aspirate aminotransferase and alanine aminotransferase, increasing the activities of the antioxidants superoxide dismutase and glutathione peroxidase, and inhibiting cellular apoptosis induced by DOX (30 mg/kg). These results demonstrate that inhibiting lipid peroxidation and reducing myocardial and hepatocyte apoptosis may be one of the mechanisms by which MgIG exhibits hepatoprotective and cardioprotective effects in DOX-treated mice.

show abstract

Drug-induced hepatotoxicity in cancer patients - implication for treatment

Cited by 69 publications

References 175 publications

A Single-Agent Dual-Specificity Targeting of FOLR1 and DR5 as an Effective Strategy for Ovarian Cancer

A Single-Agent Dual-Specificity Targeting of FOLR1 and DR5 as an Effective Strategy for Ovarian Cancer

Herbal medicine for depression and anxiety:Asystematic review with assessment of potential psycho‐oncologic relevance

Magnesium isoglycyrrhizinate ameliorates doxorubicin‑induced acute cardiac and hepatic toxicity via anti‑oxidant and anti‑apoptotic mechanisms in mice

Contact Info

Product

Resources

About